منابع مشابه
Lumiracoxib (Novartis).
Lumiracoxib, an inhibitor of cyclooxygenase 2 (COX-2), is under development by Novartis for the potential treatment of osteoarthritis, rheumatoid arthritis and pain. By late December 2000, phase III trials had been initiated and were ongoing in December 2001.
متن کاملFingolimod. Mitsubishi Pharma/Novartis.
Mitsubishi Pharma Corp and Novartis AG are developing fingolimod, an orally active immunosuppressant affecting lymphocyte re-circulation, for the potential prevention of transplant rejection and the treatment of autoimmune diseases, including multiple sclerosis. Fingolimodis a synthetic sphingosine analog that becomes phosphorylated in vivo and acts as a sphingosine-1-phosphate receptor agonist.
متن کاملThe Novartis Foundation
before — a hotbed of gene therapy research. It was a remarkable opportunity. Mulligan was offered one laboratory at the Children's Hospital to work on the basic science of viral vectors, and a second laboratory in a central Harvard building that will manufacture the vectors for use in human trials. Despite all these enticements, Mulligan did not agree to move — and leave a position at the White...
متن کاملNovartis CSR template
Study center(s): A total of 2957 centers in 27 countries enrolled at least one patient (number of centers in brackets): Argentina (15), Austria (22), Bahrain (9), Belgium (335), Bulgaria (24), Colombia (25), Czech Republic (39), Ecuador (3), Germany (790), Greece (7), India (472), Jordan (26), Republic of Korea (54), Kuwait (13), Lebanon (53), Luxembourg (2), Mexico (264), Netherlands (129), Om...
متن کاملNovartis scientists target resistance threat in malaria
Global Impact [2] In a medical treatment facility on the Thai-Burmese border, 21 patients infected with malaria recently participated in a clinical trial. All 21 patients left the facility with no trace of the disease, a finding reported in the July 31 issue of the New England Journal of Medicine. That might not sound unusual — several malaria treatments are available — but as the first signs o...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Nature Biotechnology
سال: 1997
ISSN: 1087-0156,1546-1696
DOI: 10.1038/nbt0397-211a